Featured Research

from universities, journals, and other organizations

Young women most at risk least likely to be offered HPV vaccine

Date:
March 17, 2014
Source:
BMJ-British Medical Journal
Summary:
Young women who are most at risk of developing cervical cancer are the least likely to be offered the protective HPV jab and to complete the full course when they are, reveals research. These women need to be better targeted to boost the overall uptake of the vaccination program, which was well below the 80% required to make a significant difference to cervical cancer rates during its first three years of operation, say the authors.

Young women who are most at risk of developing cervical cancer are the least likely to be offered the protective HPV jab and to complete the full course when they are, reveals research published online in the journal Sexually Transmitted Infections.

These women need to be better targeted to boost the overall uptake of the vaccination program, which was well below the 80% required to make a significant difference to cervical cancer rates during its first three years of operation, say the authors.

They base their findings on responses to anonymous questionnaires completed by 2247 young women aged 13 to 19, and comparative national lifestyle data for this age group.

All the participants were attending sexual health clinics located in 19 hospitals and 13 community services across England between March and August 2011.

The survey respondents had much higher rates of factors known to increase the risk of developing cervical cancer than their peer group, as evidenced from the national data.

These included smoking -- 48% vs 14% of 15 year olds -- first sex under the age of 16 -- 52% vs 38% (among 16-19 year olds) -- and previous sexually transmitted infections -- 25% vs 4%.

Twice as many survey respondents as the population average were not in education, training or work, known as NEETs (8% vs 2%). They also had a higher prevalence of smoking and more sexual partners.

Three out of four (74%) respondents had been offered the HPV jab, mostly in schools (60%).

But this overall rate was significantly lower among those living in London (66%); those whose ethnicity was not white (64-69%); 17 to 19 year olds (67%); NEETs (49%); smokers (69%); and those with a previous sexually transmitted infection (63%).

While two thirds (65%) of those offered the jab, took it up, completion rates were significantly lower among London respondents (58%); non-white ethnicities (42-56%);17 to 19 year olds (62%); NEETs (48%); smokers (59%); and those with a previous sexually transmitted infection (53%).

Over half (57%) of those who refused the jab when offered it, said they might have accepted if they/their parents/friends had been better informed about its purpose, while around one in five (22%) said they had not been followed up.

Low participation in the HPV vaccination program puts these women at risk of developing cervical cancer, and may also extend into adulthood and so affect their uptake of cervical cancer screening, warn the authors.

Low participation may also undermine the effectiveness of the program, they add.

"Although the [Department of Health] has no explicit targets for vaccine completion, modelling work predicted a significant impact on cervical cancer deaths with an 80% uptake of all three doses," they write.


Story Source:

The above story is based on materials provided by BMJ-British Medical Journal. Note: Materials may be edited for content and length.


Journal Reference:

  1. Rachel J Sacks, Andrew J Copas, Dawn M Wilkinson, Angela J Robinson. Uptake of the HPV vaccination programme in England: a cross sectional survey of young women attending sexual health services. Sexually Transmitted Infections, March 2014 DOI: 10.1136/sextrans-2013-051179

Cite This Page:

BMJ-British Medical Journal. "Young women most at risk least likely to be offered HPV vaccine." ScienceDaily. ScienceDaily, 17 March 2014. <www.sciencedaily.com/releases/2014/03/140317203754.htm>.
BMJ-British Medical Journal. (2014, March 17). Young women most at risk least likely to be offered HPV vaccine. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2014/03/140317203754.htm
BMJ-British Medical Journal. "Young women most at risk least likely to be offered HPV vaccine." ScienceDaily. www.sciencedaily.com/releases/2014/03/140317203754.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins